Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk patient to Coronary Heart Disease~* At visit 1(Screening)~  1. If treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study : LDL-C\<100mg/dL and 150mg/dL≤TG\<500mg/dL, randomize without run-in period~ 2. If non treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study : LDL-C≥100mg/dL and 150mg/dL≤TG\<500mg/dL, treatment of Pitavastatin 2mg for 4 weeks(run-in period)~* LDL-C\<100mg/dL and 150mg/dL≤TG\<500mg/dL after 4 weeks of Pitavastatin 2mg monotherapy~Exclusion Criteria:~* Subject with acute artery disease~* Subject with congestive heart failure(NYHA class III\~IV) or uncontrolled arrhythmia~* Secondary or iatrogenic dyslipidemia caused by hypothyroidism, nephrotic syndrome etc.~* AST or ALT \> 2XULN, Serum Creatinine \> 2.5mg/dL, Creatinine phosphokinase \> 2XULN~* Subject with gall bladder disease or pancreatitis~* Uncontrolled hypertension~* Endocrine or metabolic disease affected on serum lipid or liprotein~* Subject with medical history of myopathy or rhabdomyolysis caused by Statin treatment, hereditary myopathy or family history~* Not eligible to participate for the study at the discretion of investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HL-PIF cap.160/2mg + Placebo (Type: EXPERIMENTAL): * Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~* once a day
- Livalo tab. 2mg + Placebo (Type: ACTIVE_COMPARATOR): * Pitavastatin ca 2mg~* once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).